Nantes, France

Martine Amiot

This inventor holds 1 USPTO granted patent. Top assignee: The General Hospital Corporation. Active years: 1998.


% Patents Active = 100.0

Average Co-Inventor Count = 10.0

ph-index = 1

Forward Citations = 55(Granted Patents)


Company Filing History:


Years Active: 1998

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Martine Amiot: Innovator in Molecular Biology

Introduction

Martine Amiot is a distinguished inventor based in Nantes, France. She has made significant contributions to the field of molecular biology, particularly in the area of cloning cDNAs from mammalian expression libraries. Her innovative work has led to the development of a highly efficient method that has implications for various biological research applications.

Latest Patents

Martine Amiot holds a patent for her invention titled "CD40 coding sequences." This patent describes a simple and highly efficient method for cloning cDNAs from mammalian expression libraries based on transient expression in mammalian host cells. The present invention specifically provides the CD40 cDNA sequence, which is crucial for advancing research in immunology and related fields. She has 1 patent to her name.

Career Highlights

Martine Amiot is associated with The General Hospital Corporation, where she has been able to apply her expertise in molecular biology. Her work has not only contributed to scientific knowledge but has also paved the way for potential therapeutic applications.

Collaborations

Throughout her career, Martine has collaborated with notable scientists, including Brian Seed and Alejandro A Aruffo. These collaborations have enriched her research and expanded the impact of her inventions.

Conclusion

Martine Amiot is a remarkable inventor whose work in molecular biology continues to influence the scientific community. Her innovative methods and collaborations highlight her commitment to advancing research in her field.

Profile summary based on public USPTO records.
Please report any incorrect information to [email protected]
Loading…